The study results show that SPP100, the first-in-class direct renin inhibitor, has shown clinically meaningful reductions in left ventricular hypertrophy (LVH), a proven predictor of heart disease, that are comparable to those seen with the current standard-of-care treatment.
The Allay 36-week study treated 460 patients with SPP100, losartan or a combination of the two. Results showed that treatment with SPP100 alone reduced LVH as effectively as the angiotensin receptor blocker (ARB) losartan (-5.4% versus -4.7% respectively) after nine months of therapy, despite patients having very well-controlled baseline blood pressure. The combination of both medicines achieved a numerically greater reduction in LVH than losartan alone, but the result was not statistically significant. Alone and in combination, SPP100 was well-tolerated.
The Allay study is the latest trial in Novartis’s Aspire Higher program to highlight the organ protection potential of SPP100, the first new kind of high blood pressure treatment in more than a decade.
Chris Jensen, head of scientific affairs at Speedel, said: “This data is yet another important step forward in demonstrating the full potential of SPP100 to treat both hypertension and its consequences, which so often lead to debilitating or fatal illness.”